Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
SecuraBio
Hoffmann-La Roche
Fondazione Italiana Linfomi - ETS
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
The Lymphoma Academic Research Organisation
Fudan University
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
University Hospital Southampton NHS Foundation Trust
CTI BioPharma
Ohio State University Comprehensive Cancer Center
Acrotech Biopharma Inc.
M.D. Anderson Cancer Center
Celgene
Royal Marsden NHS Foundation Trust
The University of Hong Kong
US Oncology Research
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Istituto Clinico Humanitas
Children's Oncology Group